Orion Pharma Limited (DSE:ORIONPHARM)

Orion Pharma Balance Sheet

Financials in millions BDT. Fiscal year is July - June.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Cash & Equivalents	81.85	72.1	147.73	130.11	106.13	414.99
Short-Term Investments	66.49	54.18	45.82	38.68	31.83	23.62
Cash & Short-Term Investments	148.34	126.28	193.55	168.79	137.97	438.61
Cash Growth	9.69%	-34.75%	14.67%	22.34%	-68.54%	-58.38%
Accounts Receivable	4,373	4,390	4,210	5,584	6,796	3,943
Other Receivables	10,972	10,656	10,267	9,811	8,109	8,458
Receivables	15,345	15,046	14,477	15,395	14,905	12,401
Inventory	1,077	1,505	1,699	1,614	1,660	1,411
Prepaid Expenses	-	-	0.11	1.1	26.19	43.84
Other Current Assets	923.75	859.62	1,045	1,897	2,026	1,928
Total Current Assets	17,495	17,537	17,415	19,076	18,755	16,223
Property, Plant & Equipment	32,247	30,937	28,951	26,424	23,009	19,856
Long-Term Investments	7,401	7,322	8,067	7,440	6,343	6,254
Other Long-Term Assets	-0	-	-	-	-	-
Total Assets	57,144	55,796	54,433	52,940	48,107	42,333

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Accounts Payable	6,729	6,710	6,136	6,259	7,301	4,231
Accrued Expenses	278.75	278.28	298.44	270.03	265.44	232.48
Short-Term Debt	409.59	493.7	556.18	547.82	563.9	564.32
Current Portion of Long-Term Debt	-	-	67.35	490.5	387.47	274.33
Current Portion of Leases	14.02	14.93	13.94	23.91	31.66	36.42
Current Income Taxes Payable	334.88	321.16	304.49	435.26	398.62	262.75
Other Current Liabilities	733.59	645.99	390.05	1,444	488.23	406.06
Total Current Liabilities	8,500	8,464	7,766	9,470	9,437	6,008
Long-Term Debt	26,583	25,137	23,111	20,808	17,601	15,930
Long-Term Leases	32.16	31.69	13.71	26.35	35.27	39.9
Long-Term Deferred Tax Liabilities	453.26	402.12	315.43	157.7	122.25	138.28
Other Long-Term Liabilities	143.41	143.41	143.41	143.41	143.41	143.41
Total Liabilities	35,712	34,178	31,350	30,606	27,338	22,259

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Common Stock	2,340	2,340	2,340	2,340	2,340	2,340
Additional Paid-In Capital	8,017	8,017	8,017	8,017	8,017	8,017
Retained Earnings	6,639	6,857	7,499	7,400	6,978	6,401
Comprehensive Income & Other	3,002	2,932	3,683	3,067	1,978	1,905
Total Common Equity	19,998	20,146	21,540	20,824	19,313	18,663
Minority Interest	1,434	1,472	1,543	1,510	1,456	1,412
Shareholders' Equity	21,432	21,618	23,083	22,334	20,769	20,074
Total Liabilities & Equity	57,144	55,796	54,433	52,940	48,107	42,333

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Total Debt	27,039	25,677	23,762	21,897	18,619	16,844
Net Cash (Debt)	-26,878	-25,539	-23,552	-21,700	-18,446	-16,377
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-114.86	-109.14	-100.65	-92.74	-78.83	-69.99
Filing Date Shares Outstanding	234	234	234	234	234	234
Total Common Shares Outstanding	234	234	234	234	234	234
Working Capital	8,995	9,073	9,648	9,606	9,318	10,216
Book Value Per Share	85.46	86.09	92.05	88.99	82.53	79.76
Tangible Book Value	19,998	20,146	21,540	20,824	19,313	18,663
Tangible Book Value Per Share	85.46	86.09	92.05	88.99	82.53	79.76

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 15, 2026

Data Sources Report a data error